ImmuneBridge

San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. ImmuneBridge is based in San Francisco, CA and was founded in 2018. Its last reported valuation was $25 million in Jan 2023. It has raised $19.7 million across 2 recorded rounds; the latest was a $5.6 million early-stage round in Mar 2025.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$19.7M
Last round
Early Stage VC
Mar 2025
What is ImmuneBridge worth?
$25.0Mlast reported valuation · Oct 2026

ImmuneBridge's last reported valuation, Jan 2023. Nothing priced has surfaced since.

Free account
More of ImmuneBridge with a free account
  • ·The complete investor list: 16 names
  • ·Watch ImmuneBridge: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

ImmuneBridge funding history

2 rounds
DateRoundRaisedPost-money
Mar 2025Early Stage VC$5.6M▮
Dec 2022Early Stage VC$10.2M▮
Unlock post-money valuations

Membership and data by Private Market View

ImmuneBridge valuation

ImmuneBridge's last reported valuation was $25 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has ImmuneBridge raised?

ImmuneBridge has raised $19.7 million across 2 recorded rounds since 2022. The largest was a $5.6 million early-stage round in Mar 2025.

ImmuneBridge has filed 2 Form Ds with the SEC since 2023, most recently in Apr 2025 ($5.6 million sold to 6 investors).

How ImmuneBridge's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For ImmuneBridge, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about ImmuneBridge

What is ImmuneBridge worth?
ImmuneBridge is valued at $25.0M as of Oct 2026. ImmuneBridge's last reported valuation, Jan 2023. Nothing priced has surfaced since.
How much has ImmuneBridge raised?
ImmuneBridge has raised $19.7M in total funding across 2 recorded rounds.
When did ImmuneBridge last raise?
ImmuneBridge last raised in Mar 2025 (Early Stage VC), raising $5.6M.